ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2170 entries already.
The much-discussed digital transformation in the healthcare sector is in full swing. European Biotechnology spoke with Dr. Sabrina Graf, COO of the globally active Tenthpin Group, about how the right software can improve quality management, keep the system landscape lean, and safe both, time and money.
French Sanofi SA announced that it will acquire Dren Bio Inc’s bispecific myeloid cell engager DR-0201 for upfront US$600m and US$1.3bn in milestones. The deal is expected to close in Q2/2025.
University of Oxford spinout Brainomix Ltd has closed a £14m Series C round to advance its commercial expansion in the US. Funding will also support clinical uptake of its AI imaging technology in stroke and lung fibrosis.
The U.S. administration of President Donald Trump has revoked Executive Order 14081, “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy,” originally issued on September 12, 2022. This decision will have far-reaching consequences for the U.S. biotech industry.
Sofinnova Partners has raised €165m within its biotech acceleration fund Biovelocita II that attracted investments fromBig Pharma including Amgen, Bristol Myers Squibb, and Pfizer Ventures.
At the third attempt, the Polish Council Presidency has broken the resistance of the member states against the deregulation of crops produced by new genomic technologies (NGT). The new draft will enter trilogue discussions in April.
Spanish SpliceBio has dosed the first patient with SB-007, the first dual AAV gene therapy in clinical development for Stargardt disease
The UK Food Standards Agency (FSA) has selected eight companies to participate in a two-year regulatory programme set to speed up market approval and safety assessment of cell-cultivated products.
Roche is extending its obesity pipeline signing a US$5.3bn biobucks deal with Zealand Pharma A/S, who will co-develop and co-commercialise a monotherapy of its long-acting amylin analogue petrelintide with the Swiss pharma giant in the US and Europe and do the same for a combo of petrelintide and Roche’s GLP1/GIP receptor agonist CTT388.
Novo Nordisk A/S’ combined GLP1-, amylin- and calcitonin receptor agonist CagriSema has failed to meet the expected 25% weight loss within 68 weeks in the second of four pivotal Phase III trials. Shares in Novo Nordisk closed down 8% after the data became public.